Zydus Wellness Limited (ZYDUSWELL) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch
Zydus Wellness enters the Q1 FY27 results facing the dual challenge of integrating its international Comfort Click operations while managing a seasonal peak for domestic brands like Nycil and Glucon-D. Investors will be focused on whether the company can sustain its 17–18% EBITDA margin target amidst rising edible oil costs and a leadership transition in its sales division.
| Results date | August 04, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Previous quarter revenue | Rs. 1,476.1 Cr |
| Previous quarter PAT | Rs. 162.0 Cr |
| Previous quarter EBITDA margin | 18.2% |
| Market cap | Rs. 18007.9 Cr |
| CMP | Rs. 566.0 |
Zydus Wellness Limited Q1 Results Date and Time
The board will consider the Q1 FY27 unaudited financial results on August 04, 2026.
The company recommended a final dividend of Rs. 1.20 per share for FY26, with a record date of July 17, 2026, and payment scheduled on or after August 07, 2026.
What to expect from Zydus Wellness Limited's Q1 FY27 results
Management's path to a 17–18% EBITDA margin remains the primary focus for Q1 FY27, testing whether the company can maintain profitability despite the edible oil tariff value hike to USD 1,218/tonne effective June 1, 2026. The seasonal performance of Nycil and Glucon-D is critical this quarter, given the low base of an 18.8% decline in FY26 and the potential impact of above-normal temperatures.
While the consolidated base benefits from the Comfort Click digital VMS subsidiary—which management guided to 14%+ EBITDA margins—the core business faces pressure from rising input costs and the ongoing sales leadership transition following the resignation of the Head of Sales effective July 3, 2026. The upcoming call will likely address the impact of rupee depreciation on the EUR-denominated acquisition debt, which stood at Rs. 30,349 Mn at the end of FY26.
Key Things To Watch
EBITDA margin and cost management: Tracking progress toward the 17–18% margin target amidst inflationary headwinds.
- Core business margin trajectory vs Q1 FY26 baseline of 18.1%
- Impact of edible oil cost volatility on gross margins
- Elevated finance costs related to the EUR-denominated acquisition loan
Seasonal and segment performance: Monitoring the recovery of core brands and the contribution of the digital VMS business.
- Q1 revenue performance of Nycil and Glucon-D relative to prior year
- Like-to-like growth and EBITDA margin stability for Comfort Click
- Operational progress of new Dubai and Ireland subsidiaries incorporated in June 2026
Strategic and leadership transitions: Addressing organizational changes and reporting transparency.
- Status of the Head of Sales search and impact on distribution reach
- Potential commencement of geographical segment reporting for FY27
- Performance vs Guidance Tracking: Group EBITDA margin target of 17–18% by FY27–FY28 — status: ongoing
Ask about this
Ask Cofacto a question about this company. Answers cite filings and company data.
Frequently Asked Questions
How did Zydus Wellness's seasonal brands perform in the previous fiscal year?
Seasonal brands, including Nycil and Glucon-D, saw a revenue decline of 18.8% in FY26. This performance was largely attributed to unseasonal and extended monsoons which impacted demand.
What is the current status of the Comfort Click acquisition integration?
Comfort Click became cash EPS accretive post-interest and tax in Q3 FY26 and is guided to maintain EBITDA margins of 14% or higher. Integration is ongoing, with seven new product launches in Q4 FY26 and the recent incorporation of international subsidiaries in Dubai and Ireland.
How is the company managing its acquisition-related debt?
The Comfort Click acquisition was initially funded via a bridge loan at approximately 5% interest, which was subsequently refinanced into a EUR loan. As of the end of FY26, the company held Rs. 30,349 Mn in non-current borrowings.
Is the company on track with its EBITDA margin guidance?
The company has set a target of 17–18% EBITDA margin to be achieved over the two years following Q2 FY26. While the exit margin in Q4 FY26 was 18.2%, the full-year FY26 margin was 12.9%, indicating that the target timeline extends into FY27–FY28.